About Us
History
IPSS GmbH was founded in 2001 in the Biotechnology Park in Berlin, Germany as a Drug R&D company with offices in Berlin, Toronto and animal research facilities in Sofia and Stara Zagora (Bulgaria). IPSS was specialising in the development and execution of strategies for research and product-development as well as GMP manufacturing of innovative molecules and generic drugs. IPSS provide:
- Strategic direction in research and development with emphasis on creating New Chemical Entities (NCEs) in oncology, immunology and degenerative diseases
- Drove business development for respective company
- Planned and managed research projects from drug discovery to preclinical development, and supervised performance of multi-centre, multinational Phase I-II studies
- Monitored quality of studies, ensuring compliance with applicable regulations such as GLP, GMP and ICH-GCP
- Maintained patents/applications and trademarks, and oversaw licensing of patents and technologies
- Managed outsourcing of GLP pre-clinical, ICH-GCP clinical services and cGMP to selected CROs and drug manufacturing facilities
Dr. Salama, IPSS founder and owner, secured approximately 20 international patents as sole inventor. He built on patents to establish an innovative and profitable drug-product company. Furthermore, Dr. Salama Invented NCEs and organosilicon compounds and Siosomes® Nanotechnology.
IPSS licensed out the major parts of its patents between 2008 and 2010, but the development of research strategies and concepts for the application of the Siosomes technology and the invention of new generations of the organosilicon compounds for the specific delivery and targeting of peptides and proteins continued in addition to the invention and development of the ELPIS 207 as Anti-Alzheimer drug and for the treatment of neurodegenerative/neuromuscular degenerative disorders and as Biomarker.
IPSS-Ravensburg was established in 2017 to continue IPSS-Berlin’s initial work with the aim of accomplishing the challenging clinical development of ELPIS 207 for Alzheimer, cis-oxoplatin for gastric and solid tumours and CHP for the different therapeutic and orphan indications. This work was done in addition to the broad applications of the Siosomes ® for the delivery and targeting of oral peptides and proteins and topical applications.
Vision, Mission, And Objectives
Vision:
Create highly effective, profitable and affordable medicines through innovative development and marketing
Mission:
Application of Siosomes ® technology and patented ELPIS 207 to co-develop innovative drugs in the areas of oncology, immunology and degenerative diseases.
Objectives:
Application of own Siosomes® Technology
- Co-development of oral formulations and drugs for peptides, proteins and monoclonal antibodies (mAB) therapeutics.
- Co-development of innovative formulations and drugs for the intracellular delivery and targeting of genetic materials such as siRNA for the treatment of muscular degenerative diseases.
- Co-development of innovative oral formulations of anti-cancer agents such as cis-oxoplatin for gastric and solid tumours.
- Co-development of new generation of innovative topical applications using generic dermatological agents to improve the efficacy, reduce the dosage and the toxic effects and patient’s compliance.
- Use of Siosomes® technology for the delivery and targeting of the Brain Regions
Development of Anti-Dementia Drugs
Successful co-development of innovative drugs for unmet needs in the treatment of neurodegenerative and neuromuscular degenerative diseases using own developed and patented ELPIS 207 and metabolite.
Management
Dr. Zoser B. Salama
B.Sc., M.Sc., PhD (Biochemistry)
Managing Director
Chief Scientific Officer
Dr. Salama is an accomplished biochemist with more than 20 international commercial patents, more than 30 years of global success in the pharmaceutical industry, and a strong background in drug discovery, research and development, pharmaceutical formulations, delivery and targeting of pharmaceuticals, biologics and cosmetic – agents, and design of NCE’s.
As CEO, Senior Vice President, and Executive Chairman of various companies in Germany, the USA, Canada, and China for more than 30 years, Dr. Salama designed, established and managed numerous state-of-the-art research centers in the fields of Contract Research (CRO), Clinical Research, Pharmaceutical Formulations, Bioanalytics, Contract Manufacturing, Toxicity, Nanotechnology, and Pre-Clinical Research and Drug Development.
Dr. Salama - as CEO and President of his own company IPSS (International Strategies and Solutions), also developed numerous NCE’s in the fields of oncology, CNS, and immunology and performed numerous ICH-GCP multi-centre, multi-national Phase I-II studies. In addition, IPSS was responsible for the international coordination, management, strategic planning and performance of research projects from drug discovery to preclinical and Phase I-II clinical studies in healthy volunteers and patients.
Furthermore, Dr. Salama also developed and executed intensive coaching and training programs in the areas of the Quality Management Systems (QMS) and provided consulting services to international companies in this field.
Dr. Rajkumar Chetty
MBBS, MD, FRCPath, FFPM CCST (UK)
Managing Director
Chief Medical Officer
Dr. Chetty is a medical doctor, pathologist and certified pharmaceutical specialist registered with the General Medical Council, United Kingdom, in the specialties of Clinical Biochemistry and Pharmaceutical Medicine. He is a Fellow of the Royal College of Pathologists, UK and the Faculty of Pharmaceutical Medicine, The Royal College of Medicine, UK. He also has many years of experience in Pharmaceutical drug development having worked at AstraZeneca.
Dr. Chetty has Principal Investigator experience in a number of early phase clinical trials across all therapy areas. He has a strong background in exploratory drug development and biomarker research. He has experience of working in cross pharma external consortia within Europe in safety biomarkers (IMI, DTI, PSTC), interacting with experts in other Pharma companies and academic leaders.
Dr. Chetty was AstraZeneca’s expert representative in the IMI safety biomarker consortium and an expert member of AstraZeneca’s Global Advisory Panel for Hepatotoxicity during his tenure at AstraZeneca. He was also an Expert member of AstraZeneca’s Global Advisory Panel for Nephrotoxicity and a member of AstraZeneca’s Safety Biomarker Support Team.
Dr. Andera Salama-Mueller
Medical Director
Senior medical consultant for internal medicine and gastroenterology at the St. Elisabeth hospital in Ravensburg, Germany and runs her own practice. In addition, Dr. Salama-Mueller is one of two partners in SMMC (Salama-Mueller Medical Consulting) with special focus on the coordination and execution of clinical studies, medical expert statements, and senior medical coaching, Consulting and seminars. Her combined experience spans more than 15 years.
Dr. Berno Mueller
Medical Director
Senior medical consultant for general medicine and nutrition and is the medical director of Vifor Pharma Germany, the German Affiliate of the global leader in Iron Therapy and additional Focus in cardiorenal medicine. He holds a Bachelor in International Economics from the GSBA business school in Zurich, Switzerland. In addition, Dr. Mueller is a teaching professor of health economics at the University of Applied Sciences in Neu-Ulm. Furthermore, Dr. Mueller is one of two partners in SMMC (Salama-Mueller Medical Consulting) with special focus on the coordination and execution of clinical studies, medical expert statements, and senior medical coaching, Consulting and seminars. His combined experience spans more than 25 years.
Magdy Salama
B.Sc., MBA
Business Director - authorised signatory
Business professional with over 25 years of experience in international strategy, marketing, business development, transformation/change management, and general management (GM/Managing Director). Mr. Salama worked for several Fortune 500 companies, such as NIKE and Hewlett Packard in various senior business roles across multiple countries on four continents, allowing him to integrate cultural context, local/regional conditions and business practices. His experience and expertise across different areas in business allows him to translate challenges into opportunities through holistic, results driven hands-on plans, programs, and executions that deliver strong brand positioning and business growth which add value for shareholders, stakeholders and employees. He has extensive experience in the establishment, management and development of budgets and teams on a global and regional scale including organisational development and auditing. Mr. Salama holds a Bachelor in Industrial Management from the University of Aberdeen in Scotland / UK and an MBA (Master of Business Administration) from the University of Saint Xavier in Chicago / USA.